Skip to content

Released Aug 14, 2025, before the open

10-Q filed Aug 14, 2025, 45 days after period end · 0001785530-25-000021

Q2 2025 · 10-Q
Revenue—
Net Income-$17.98MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.40N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$17,542,000N/M
Operating Cash Flowderived-$15,164,000N/M
Free Cash Flowderived-$15,164,000N/M

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Net Income-$17.98M-$17.25M-$5.10M-$14.59M
EPS Diluted-$0.40-$0.43-$0.14-$0.53

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR